Novartis To Pay $25M To Settle International Bribery Claims In SEC Action
WASHINGTON, D.C. — Pharmaceutical company Novartis AG will pay $25 million to settle claims that it violated provisions of the Foreign Corrupt Practices Act (FCPA) by engaging in “pay-to-prescribe” scheme to...To view the full article, register now.
Already a subscriber? Click here to view full article